fda peptide warning 2025 september Warning - FDAZepbound WARNING FDA Peptide Warning 2025 September: Navigating Regulatory Actions and Safety Concerns

FDAboxedwarning The landscape of peptide-based therapeutics and their associated regulatory oversight is rapidly evolving. In September 2025, the FDA has issued a series of significant warning letters and taken other regulatory actions, particularly concerning peptide products and GLP-1 receptor agonists2025年9月9日—WARNINGLETTER.September 9, 2025. Try Nova: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed .... These actions highlight a heightened focus on product safety, efficacy, and proper marketing, underscoring the FDA's commitment to protecting public health.They won't get the real medication in "GLP-1 patches," doctors warn. Sept. 19, 2025, 8:31 AM PDT / Source: TODAY ... There are also no FDA-approved drug ...

A key development in September 2025 was the FDA's issuance of warning letters to over 50 companies involved in the compounding of GLP-1 and peptide products. This broad action indicates a widespread concern regarding the manufacturing practices and quality control of these substances2025年9月23日—FDAplaced all drugs and drug products offered for import into the United States from your firm on ImportAlert66-40 on July 9,2025.. Specifically, Eli Lilly and Company and Novo Nordisk Inc.2025年12月9日—Notably, this comes as theFDAintroduced a so-called “Green List” inSeptember 2025: a mechanism aimed at preventing potentially unsafe active ..., major players in the GLP-1 market, received warning letters on September 9, 2025.2024年3月5日—The products concerned are the new drugs "Semaglutide", "Tirzepatide" and "Thymalin", which have not been approved by theFDAand have been marketed or ... These letters addressed issues related to their promotional materials and direct-to-consumer programs, with An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025 being a prominent example. These warning letters often cite the risk of thyroid C-cell tumors, a concern associated with certain GLP-1 receptor agonists like Zepbound.

In addition to direct warning letters, the FDA has implemented proactive measures to curb the influx of potentially unsafe peptide products. On September 05, 2025, the FDA established a "Green List" import alert. This initiative aims to prevent the import of active pharmaceutical ingredients (APIs) with potential quality concerns, including GLP-1 APIs. This measure, coupled with an ImportAlert 66-40 placed on drugs from Chengdu Brilliant Biopharmaceutical Co., Ltd. on July 9, 2025, demonstrates the FDA's intensified efforts to control the supply chain and prevent the distribution of unapproved or substandard peptide products2025年12月9日—Notably, this comes as theFDAintroduced a so-called “Green List” inSeptember 2025: a mechanism aimed at preventing potentially unsafe active .... The FDA's action on September 16, 2025, to release more than 60 warning and untitled letters further emphasizes the agency's robust enforcement posture.

The FDA's regulatory scrutiny extends to various aspects of peptide products. For instance, Ralph A. DeFronzo, M.D.FDA Launches Green List to Protect Americans from Illegal ..., and GLP-1 Solution received warning letters on September 17, 2025, and September 9, 2025, respectively, detailing objectionable conditions observed during FDA inspections. Similarly, PureRawz MARCS-CMS was flagged on September 08, 2025, for marketing unapproved new drugs, including Tianeptine productsFDA issues warning letters to USA Peptide and Empower .... The FDA's stance on compounded peptides is also evident in their actions against companies like USA Peptide and Empower Pharmacy, which received warning letters in February 2025 and September 18, 2025. This collective action underscores the FDA's concern that "Big Pharma says compounded peptides are 'unsafe'," while simultaneously facing FDA warning letters for their own product quality issues2026年1月13日—FDA Requests Removal of Suicidal Behavior and Ideation Warningfrom Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications..

Furthermore, the FDA has been actively reviewing and, in some cases, requesting the removal of specific safety warnings from drug labels. For example, the FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, as noted in documents from January 13, 2026, and January 14, 2026, suggesting a re-evaluation of certain adverse event profiles.February 26, 2025:FDAissued aWarningLetter to USAPeptide. The ... (2025,September18). A Prescription for Action: A Pan-Canadian ... This contrasts with the FDA's earlier actions, such as the FDAboxedwarning regarding the risk of thyroid C-cell tumors for Zepbound.

The broader context of these actions includes the FDA's recognition of the growing use of unapproved peptides by Americans. The FDA's efforts in September 2025 to address these concerns are multifaceted, encompassing enforcement actions, import alerts, and public advisories. The FDA's "Green List" initiative, launched on September 05, 2025, is a significant step in this direction, aiming to proactively prevent the entry of potentially harmful substancesLilly, Novo, Hims Get FDA Warnings About Misleading ....

While the FDA continues to approve novel drugs, including peptide-based therapeutics, as seen in the 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest where 46 novel drugs were approved, including one peptide, the September 2025 regulatory actions highlight a critical period of increased oversight2024年3月5日—The products concerned are the new drugs "Semaglutide", "Tirzepatide" and "Thymalin", which have not been approved by theFDAand have been marketed or .... The FDA's actions serve as a crucial reminder that while peptide therapies hold immense promise, adherence to regulatory standards and rigorous safety protocols are paramount. The FDA's commitment to ensuring the safety and efficacy of all drug products, including those in the rapidly advancing field of peptide therapeutics, remains a top priority. The FDA's ongoing efforts, including those in 2025, are vital for maintaining public trust and safeguarding health.